NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$37.25 +0.25 (+0.68 %)
(As of 07/22/2018 01:15 AM ET)
Previous Close$37.25
Today's Range$36.75 - $37.55
52-Week Range$26.95 - $49.80
Volume316,108 shs
Average Volume542,331 shs
Market Capitalization$1.51 billion
P/E Ratio-64.22
Dividend YieldN/A
Beta1.79
Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Debt-to-Equity Ratio1.00
Current Ratio8.66
Quick Ratio7.83

Price-To-Earnings

Trailing P/E Ratio-64.22
Forward P/E Ratio-67.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$286.63 million
Price / Sales5.29
Cash Flow$0.0618 per share
Price / Cash602.36
Book Value$6.89 per share
Price / Book5.41

Profitability

EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-11.45%
Return on Equity-5.81%
Return on Assets-2.56%

Miscellaneous

Employees489
Outstanding Shares40,730,000
Market Cap$1,507.09

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced its earnings results on Thursday, May, 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $0.02. The firm had revenue of $74.61 million for the quarter, compared to analyst estimates of $73.92 million. Pacira Pharmaceuticals had a negative net margin of 11.45% and a negative return on equity of 5.81%. Pacira Pharmaceuticals's revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.19) earnings per share. View Pacira Pharmaceuticals' Earnings History.

When is Pacira Pharmaceuticals' next earnings date?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacira Pharmaceuticals.

What price target have analysts set for PCRX?

21 Wall Street analysts have issued twelve-month target prices for Pacira Pharmaceuticals' shares. Their forecasts range from $27.00 to $80.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $45.1765 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Ratings for Pacira Pharmaceuticals.

What is the consensus analysts' recommendation for Pacira Pharmaceuticals?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 1 sell rating, 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product-Exparel. It is making efforts to expand Exparel's label. In April 2018, the FDA approved Pacira’s sNDA seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. However, the company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. This is a concern for the company. Exparel also competes with well-established products for postsurgical pain management." (7/15/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018)
  • 3. Mizuho analysts commented, "We switched from Symphony Health data last month, after a sizeable data restatement from the vendor rendered our prior estimates unreliable." (6/29/2018)
  • 4. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:
  • Mr. David M. Stack, Chairman & CEO (Age 68)
  • Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
  • Dr. Richard Scranton M.D., MPH, Chief Scientific Officer (Age 57)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 44)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)

Has Pacira Pharmaceuticals been receiving favorable news coverage?

News headlines about PCRX stock have been trending positive this week, according to Accern. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a news sentiment score of 0.26 on Accern's scale. They also gave news stories about the company an impact score of 44.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Pacira Pharmaceuticals' major shareholders?

Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.43%), Peregrine Capital Management LLC (0.66%), Bank of Montreal Can (0.09%), Pendal Group Ltd (0.06%), Xact Kapitalforvaltning AB (0.02%) and Benjamin F. Edwards & Company Inc. (0.01%). Company insiders that own Pacira Pharmaceuticals stock include Charles A Reinhart III, David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Which institutional investors are selling Pacira Pharmaceuticals stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can and Benjamin F. Edwards & Company Inc.. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Charles A Reinhart III, David M Stack, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.

Which institutional investors are buying Pacira Pharmaceuticals stock?

PCRX stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Xact Kapitalforvaltning AB and Pendal Group Ltd. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy shares of Pacira Pharmaceuticals?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of PCRX stock can currently be purchased for approximately $37.25.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.51 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  587 (Vote Outperform)
Underperform Votes:  366 (Vote Underperform)
Total Votes:  953
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.